创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: What is the application value of iHuPBMC-T platform?

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-25 10:20
  • Views:

(Summary description)With the rapid development of biotechnology, immunology research has gradually penetrated into the cellular and molecular level. In this context, the iHuPBMC-T platform launched by InnoModels Biotechnology is becoming an important tool in the field of immunology research by virtue of its unique technical features and application value

InnoModels Biotechnology: What is the application value of iHuPBMC-T platform?

(Summary description)With the rapid development of biotechnology, immunology research has gradually penetrated into the cellular and molecular level. In this context, the iHuPBMC-T platform launched by InnoModels Biotechnology is becoming an important tool in the field of immunology research by virtue of its unique technical features and application value

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-25 10:20
  • Views:
Information

With the rapid development of biotechnology, immunology research has gradually penetrated into the cellular and molecular level. In this context, the iHuPBMC-T platform launched by InnoModels Biotechnology is becoming an important tool in the field of immunology research by virtue of its unique technical features and application value.
1、Advanced MHC knockdown technology
MHC (major histocompatibility complex) genes play a crucial role in the immune system and are closely related to the processes of immune response, immune recognition and immune regulation. However, the high degree of polymorphism in MHC genes poses a great challenge to immunological research. The iHuPBMC-T platform of InnoModels Biotechnology has successfully realized the knockdown of MHC gene by using advanced gene editing technology. This technological breakthrough provides a new perspective for immunological research, enabling researchers to explore the function and mechanism of the immune system more deeply under the condition of MHC deletion.

 


2. Revealing the mechanism of immune tolerance and rejection
The mechanism of immune tolerance and rejection is one of the core contents of immunological research. Through MHC knockdown, the iHuPBMC-T platform provides an ideal experimental tool for studying the mechanisms of immune tolerance and rejection. With the help of this platform, researchers can simulate the immune response process under different MHC genotypes, revealing how the immune system recognizes and handles its own tissues, foreign antigens and other complex issues. This research not only helps to understand the basic principles of the immune system, but also provides new therapeutic strategies for organ transplantation and autoimmune diseases.
3、Promote the development of personalized immunotherapy
With the rise of precision medicine, personalized immunotherapy has become a research hotspot in the field of immunotherapy. The iHuPBMC-T platform of InnoModels Biotechnology provides strong support for the development of personalized immunotherapy by simulating the immune response under different MHC genotypes. With the help of this platform, researchers can design more accurate and effective immunotherapy programs for specific individuals' immune system characteristics. This will not only improve therapeutic efficacy and reduce side effects, but also bring benefits to more patients with immunomodulatory diseases.
In conclusion, the iHuPBMC-T platform of InnoModels Biotechnology is becoming an important tool in the field of immunology research by virtue of its advanced MHC knockdown technology, its unique features in revealing the mechanisms of immune tolerance and rejection, and its ability to drive the development of personalized immunotherapies. In the future, with the continuous improvement of the platform's technology and the expansion of its application areas, we believe that it will play an even more important role in the field of immunotherapy and make greater contributions to human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司